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ABSTRACT: In the early 1900s, the abnormal toxicity test (ATT) was developed as an auxiliary means to ensure safe and consistent antiserum
production. Today, the ATT is utilized as a quality control (QC) release test according to pharmacopoeial or other regulatory requirements.
The study design has not been changed since around 1940. The evidence of abnormal toxicity testing as a prediction for harmful batches is
highly questionable and lacks a scientific rationale. Numerous reviews of historical ATT results have revealed that no reliable conclusions
can be drawn from this QC measure. Modern pharmaceutical manufacturers have thorough control of the manufacturing process and
comply with good manufacturing practice rules. Contaminants are appropriately controlled by complying with the validated manufacturing
processes and strict QC batch release confirming batch-to-batch consistency. Recognizing that product safety, efficacy, and stability can
be ensured with strict QC measures, nowadays most regulatory authorities do not require the ATT for most product classes. In line with
the replacement, reduction, and refinement (3Rs) initiative, the test requirement has been deleted from approximately 80 monographs of
the European Pharmacopoeia and for the majority of product classes in the United States. For these reasons, it is recommended that the
ATT should be consistently omitted world-wide and be removed from pharmacopoeias and other regulatory requirements. C© 2014 Wiley
Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:3349–3355, 2014
Keywords: abnormal toxicity test; analysis; biotechnology; general safety; innocuity test; pharmacopoeia; quality control; regulatory
science; toxicity; vaccines
INTRODUCTION
The abnormal toxicity test (ATT) [European Pharmacopoeia
(EP) nomenclature]1 is also referred to as the general safety
(US reference)2 or innocuity test (WHO nomenclature).3 The
principle of this animal test consists of a single injection of a
specified volume of a product batch into guinea pigs and/or mice
Abbreviations used: 3Rs, replacement, reduction, and refinement; ATT,
abnormal toxicity test; EMA, European Medicines Agency; EP, European
Pharmacopoeia; FDA, US Food and Drug Administration; GMP, good
manufacturing practice; QC, quality control.
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followed by an observation period. Typically, a batch passes the
test if the findings seen in animals follow the below criteria:
1. animals survive the test period;
2. animals do not exhibit any response, which is not spe-
cific for or expected from the product and may indicate a
difference in its quality; and
3. animals weigh not less at the end of the test period than
that at the time of injection.2
The ATT was developed in the early 1900s, when produc-
tion processes and quality control (QC) for biological products
were poorly established and licensing procedures did not yet
exist. At this time, the test was intended to ensure the safe and
consistent production of serum products, for example, to titrate
the preservative phenol level of diphtheria antiserum. Ana-
lytical techniques were not available to appropriately detect
phenol in serum products. Therefore, mice—as a susceptible
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species—were used for the detection of potentially toxic phenol
levels. The test with guinea pigs was introduced around 1900
as a biological indicator for the presence of tetanus toxin in
antiserum preparations.4,5
The test was later expanded to a general safety test to de-
tect extraneous contaminants (other than, for example, bacte-
rial endotoxins) in biological products. In spite of significant
evolution of analytical techniques as well as advanced process
understanding and validation approaches, this biological test
remains and changed from being an analytical test to an addi-
tional safety test intended to detect product/process contami-
nants to avoid batch-to-batch differences in quality.
The test has not significantly changed since around 1940.
National implementation leads to today’s variations between
the different pharmacopoeias/international requirements.
Table 1 presents requirements from the pharmacopoeias of
Europe,1 the United States,2 Russia,6 and China7 as well as
WHO requirements.3
Of note, the administration volumes in the case of in-
travenous (i.v.) dosing do not comply with today’s best
practices and animal welfare considerations. According to
Diehl et al.,8 a maximum of 5 mL/kg should be administered
to mice, which would result in a maximum volume of 0.1 mL
for mice with a body weight of around 20 g. Following the phar-
macopoeias/requirements (0.5–1.0 mL administration volume),
a mouse receives 5–10-fold of the volume considered good prac-
tice.
HISTORICAL DATA ANALYSES
Publications by the German Paul Ehrlich Institute provide ev-
idence that the test does not serve its purpose and does not
add any further information to that already obtained from
QC release testing under good manufacturing practice (GMP).9
A retrospective analysis of several thousand test results con-
ducted for vaccines revealed that there were no true posi-
tive results10,11 and no batch rejection was obtained by the
authority.12 In conclusion, there is no evidence that the ATT
is useful as a predictor or control for harmful batches. Table 2
presents details on the analysis of historical data fromKraemer
et al.12
As a result of the historical experience, theUSFood andDrug
Administration (FDA) amended the respective regulations re-
garding general biological products standards by adding an ad-
ministrative procedure for obtaining exemptions from the test
requirements.13 A similar conclusion was drawn by the Euro-
pean agency, and the test was removed from over 80 product
monographs.11,14 For details, see the section given below.
TEST PERFORMANCE
Specificity (False Positive Results)
The ATT is nonspecific, as many factors other than contami-
nants can influence the result (e.g., body weight, species and
strain differences, stress levels of the animals). Accordingly,
misinterpretation of responses caused by the active ingredi-
ents themselves, or formulation components, may lead to false
positive results, for example, as administered concentrations
may be unrealistically high compared with what is adminis-
tered to humans.15 The formulations are optimized for safe use
in humans but not in mice or guinea pigs at such high concen-
trations.
Depending on the test design, a fixed volume is administered,
irrespective of the dose used in humans. Thus, the full human
dose may be administered to guinea pigs of 250–400 g body
weight.1 In this case, assuming a human body weight of 60 kg,
a guinea pig would receive 150-fold of the human dose. Amouse
of 20 g would receive 3000-fold of the human dose.
As already mentioned, formulation components (e.g., preser-
vative and vaccine adjuvants) may cause false positive re-
sponses. There are some examples of drug products that have
yielded false positive test results:
 A response following intraperitoneal injection of high con-
centrations of benzyl alcohol, which is used as a formula-
tion component for a recombinant protein.
 A reaction caused by the high sugar content in an oral pe-
diatric vaccine, when administered according to a national
pharmacopoeia by i.v. injection.
Reproducibility
Kraemer et al.12 investigated the test reproducibility if the
ATT is performed with strict adherence to the same study
design/protocol (German Pharmacopoeia DAB 10). Identical
batches tested in different laboratories have produced signifi-
cantly different test results. Positive results never showed a cor-
relation with product quality or contamination, and the same
batches passed the ATT in subsequent test repetitions.
In addition, the ATT design is not harmonized and varies
between national pharmacopoeias/international requirements
(Table 1).
We conclude that test responses of the same batch may be
unpredictable and may give contradictory results if performed:
 repeatedly in the same laboratory,
 in different laboratories according to the same protocol,
and
 in different countries according to different protocols.
Reliability
Reliability is a measure of consistency/reproducibility. Consid-
ering the lack of reproducibility, the ATT must be classified as
unreliable.
Suitability
For common analytical procedures (e.g., quantitative tests for
impurities’ content), it is mandatory to demonstrate suitability
for the intended purpose. Typical parameters of such validation
are precision (repeatability) and specificity.16 The ATT is nei-
ther reproducible nor specific. Accordingly, the ATT would not
fulfill international validation criteria of analytical methods.
No adequate positive control is possible as the test seeks
for unknown contamination and nonspecific toxicity. Further-
more, the ATT lacks explicit acceptance criteria, as no definite
endpoint is defined (“signs of ill health,”1 “significant signs of
toxicity,”3 and “abnormal reaction”7).
In conclusion, this animal test is considered as not suitable
for its intended purpose.
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Table 2. Retrospective Analysis of Abnormal Toxicity Tests of
Vaccine Products, Test Results, and Number of Animals12
Number of
Tests
Analyzed
Preparations Used Mice
Used Guinea
Pigs
Batch
Rejections
5896 416 30193 12420 0
Would Modification Lead to an Improved Test Performance?
Mizukami et al.17 made an effort to improve the ATT design for
vaccines (Fig. 1). It is based on the observation that body weight
changes of animals are characteristic for each vaccine, and such
standardized changes can be used as references for evaluating
vaccines. In addition to body weight analysis, histopathological
and hematological analyses are proposed in case of required
retests.
In our opinion, this modified scheme does not overcome the
principal deficiencies of the test as discussed above, or the in-
herent variations of the animal model. This variability is also
evident in the fact that still up to two retests are foreseen in the
scheme. Furthermore, the test design is not considered appro-
priate to be used as a routine QC release test due to the high
experimental efforts (statistical and pathological/hematological
analysis) and the long test duration (several weeks including
retests). From an ethical perspective, such studies are not in
line with animal welfare considerations as a significant num-
ber of animals are used for the initial statistical analysis (in
order to standardize body weight changes after inoculation of
various vaccines) and the potential retests.
CONTROL OF CONTAMINANTS
Scientifically, there is no rationale as to why an animal test
for batch release would be more appropriate than other mea-
sures to detect and control contamination. For such a test to be
adequate and useful, a clear understanding of the mechanism
of how contaminations lead to the study read-out, i.e. positive
result, should be in place.
Furthermore, it should be known based on the understand-
ing of the manufacturing process what potential contaminants
might be and of what nature they could be. The endpoints and
acceptance criteria should be deduced from this understanding
so that any QC test can be appropriately validated.
Modern methodologies, such as those presented in Table 3,
are far better suited and have a clear scientific rationale be-
cause the relationship between the measured endpoint and the
causing contamination (e.g., bacterial endotoxin) is well under-
stood and established.
A set of measures are nowadays available to detect and con-
trol different types of contaminants. These include:
 extended product characterization during process devel-
opment and process validation,
 manufacture according to GMPs, and
 routine QC release testing, which verifies batch-to-
batch consistency and ensures that a specific batch has
been manufactured according to the previously validated
process.
Table 3 lists the current control measures used to verify the
absence of certain contaminants in a product batch, exemplified
by parenteral preparations.11,14
MODERN PRODUCT DEVELOPMENT ENSURES
COMPREHENSIVE PROCESS UNDERSTANDING AND
WELL-CHARACTERIZED PRODUCTS
Nowadays, pharmaceutical manufacturing is highly regulated
and controlled. The modern pharmaceutical industry together
with regulatory authorities have established appropriate con-
trol of the manufacturing process through substantially ad-
vanced process understanding, in-process controls, validation
Figure 1. Proposed test scheme according to Mizukami et al.17
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Table 3. Measures to Verify the Absence of Different Types of
Contaminants (Examples)
Type of
Contaminant
Measure to Verify the Absence of
Contaminants in a Product Batch
Microbiological – Bioburden test (in-process control)
– Sterility test
Pyrogena – Validation of depyrogenization (as part of
the process validation)
Endotoxin – Bacterial endotoxins (limulus amebocyte
lysate) test
Residual
contaminantsb
– Extended product characterization
– Process validation
– Manufacture under GMP
– QC during batch release to confirm
batch-to-batch consistency
aThe formerly used rabbit pyrogens test has been replaced by the generally
accepted bacterial endotoxins test in numerous EP monographs.11
bThe formerly used abnormal toxicity test has been deleted based on historical
review in numerous EP monographs.11,14
of the manufacturing process, and release testing complying
with international GMP standards.
During formulation and process development, many stud-
ies are conducted with different formulation components
(including preservatives) to investigate degradation profiles,
product compatibility with various materials/surfaces, and
leachables, which may be sources for contaminants.18–21 Phar-
maceutical compounds are tested extensively with regard to
their safety/toxicity profile in in vitro assays and animals mod-
els as well as in clinical trials in accordance with international
(e.g., International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human
Use) and national guidelines. A marketing authorization is
granted by the relevant health authorities only when a posi-
tive benefit/risk assessment can be demonstrated.
Today, pharmaceutical manufacturers produce highly
developed medicines with well-defined purity and safety char-
acteristics. Risk of contamination is extremely low if a man-
ufacturer complies with GMP rules (e.g., globally recog-
nized regulations22–25) and if consistency in production is
guaranteed.26,27 Abnormal product contamination is extremely
unlikely if the validated manufacturing process is followed.
Appropriate analytical methods (e.g., mass spectrometry ap-
plications) are capable of detecting contamination and ensure
batch-to-batch consistency. Advanced product testing is applied
for the extended product characterization and release testing.
RELEASE SPECIFICATIONS ARE SET ACCORDING TO
INTERNATIONAL REQUIREMENTS AND ENSURE
PRODUCT SAFETY, EFFICACY, AND STABILITY
Many multinational manufacturers supply innovative
medicines globally. Thus, a batch is usually released for use in
the global market. Accordingly, all countries get the same high
quality drug. In line with international regulations, in most
instances abnormal toxicity testing is not part of the release
specifications for these globally marketed products. For exam-
ple, European Medicines Agency (EMA)- and FDA-approved
specifications for commercial drug products do not require
abnormal toxicity testing as part of the QC release analysis
for the majority of product classes. However, a batch already
released for EU and/or the United States would have to be
tested for abnormal toxicity in other countries, for example,
the Russian Federation6 and China,7 to be released for the
local market. To the best of our knowledge, no batch which met
the EMA- or FDA-approved specifications delivered a positive
ATT result in both of these countries (apart from false positive
test results, as aforementioned).10–12
INCREASING INTERNATIONAL CONVERGENCE
Several health authorities have conducted an evaluation of the
ATT and came to the same conclusion.
European Pharmacopoeia generally does not require ab-
normal toxicity testing in the monographs for “parenteral
preparations,”28 “monoclonal antibodies for human use,”29 or
“products of recombinant DNA technology.”30 Aforementioned
reviews of test results revealed that no additional value could
be concluded from abnormal toxicity testing. As a consequence,
and in accordance with the European Convention on the Pro-
tection of Vertebrate Animals used for Experimental and other
Scientific Purposes, the test has been deleted from approx-
imately 80 monographs for biotechnological products, blood
products, antibiotics, and vaccines based on the review of
historical data.11,14 In addition, further replacement alterna-
tives for abnormal toxicity testing for batch release of ex-
isting vaccines have been currently evaluated and strongly
recommended.10,31–35
The US Code of Federal Regulations Title 21 requires gen-
eral safety testing be done for biological products (21 CFR, Part
610.112). However, FDA realized that “after more than a decade
of experience with these products, we found that we could eval-
uate many aspects of a biological product’s safety, purity, or
potency with tests other than those prescribed in part 610.”13
Thus, the FDA amended the biologics regulations regarding
general biological products standards by adding an administra-
tive procedure for obtaining exemptions from the general safety
test requirements13: 21 CFR, Part 601.2 (Ref. 36) specifies that
the test is exempted as a requirement for license applications
for therapeutic DNA plasmid products, therapeutic synthetic
peptide products of 40 or fewer amino acids, monoclonal anti-
body products for in vivo use, or therapeutic recombinant DNA-
derived products.
In 2002, the WHO Expert Committee on Biological Harmo-
nization “noted that, in one region of the world, the abnormal
toxicity test had been deleted formost products. This was linked
to the implementation of, and compliance with, good manufac-
turing practices and, where this occurred, there was abundant
evidence that the abnormal toxicity test did not provide addi-
tional assurances of the quality of the product.”37
ANIMAL WELFARE
The EU adopted a new directive on the protection of animals
used for scientific purposes (2010/63/EU38). The directive plays
a significant role in minimizing the number of animals used
in experiments and the European Directorate for the Quality
of Medicines & HealthCare continues to push forward the im-
plementation of replacement, reduction, and refinement (3Rs)
alternatives.39
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The substantial number of laboratory animals used for the
ATT cannot be justified in view of its unproven and question-
able suitability to detect contaminants and increase the prod-
uct safety.15 As a consequence, the European Convention on
the Protection of Vertebrate Animals used for Experimental and
other Scientific Purposes reviewed the test for 3Rs. As afore-
mentioned, the test has been consequently deleted from nu-
merous EP monographs.11,14
CONCLUSIONS
The ATT was implemented in the early 1900s as auxiliary
means for production, i.e., to titrate the level of the preser-
vative phenol in antiserum preparations, and has persisted for
the detection of contaminants, without clear rationale and rea-
soning. The test lacks scientific merit and is neither specific,
reproducible, reliable, nor suitable for the intended use. Con-
sidering its performance, the ATT is regarded as not appropri-
ate as a QC release test, which should be capable of enabling
batch release decisions based on explicit and reproducible
results.
A retrospective analysis of several thousand test results re-
vealed that no true positive result and no batch rejection were
obtained. Positive results never showed a correlation to the
product quality or contamination. Accordingly, the test does not
provide added value for QC. This conclusion was also drawn by
the FDA considering that safety, purity, and potency of products
are ensured without the ATT.
The ATT has therefore been deleted from numerous product
monographs, and test exemptions are granted formany product
classes, respectively. However, the test is still required as a
safety test according to a number of pharmacopoeias and other
regulatory requirements for certain product classes.
Based on the rationale provided in this review and in line
with the scientific knowledge and regulatory trends outlined
herein, it is considered fully justified to completely eliminate
abnormal toxicity testing from pharmacopoeias and other reg-
ulatory requirements as already recommended by various sci-
entific experts.12,15,35,40,41 This would also be in agreement with
animal welfare concerns (e.g., 3Rs initiatives) and contempo-
rary directives on the protection of animals.
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